These encouraging efficacy data and the potentially favorable safety profile of TGFβ1 isoform-selective inhibition establish a strong rationale for exploring therapeutic application of combining PD-(L)1 blockade with latent TGFβ1 inhibition in treatment of multiple cancer types. This evidence concerns the gene CD274 and cancer.